Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 7/2011

01.07.2011 | Leading Article

Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder

Current Status of Knowledge

verfasst von: Yu-Shu Huang, Dr Ming-Horng Tsai

Erschienen in: CNS Drugs | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Attention-deficit hyperactivity disorder (ADHD), a common neuro-behavioural disorder characterized by inattention, hyperactivity and impulsivity, is a chronic disorder and often persists into adulthood. CNS stimulants have been the most well known treatment for ADHD for several decades due to their high effectiveness, good safety profiles and relatively minor adverse effects. Non-stimulant agents, including atomoxetine, extended-release guanfacine and extended-release clonidine (US FDA approved), and several non-FDA-approved agents, such as bupropion and tricyclic antidepressants (TCAs), were recently proven to be effective alternatives to the stimulants in several open-label and placebo-controlled trials. However, most medication trials for ADHD have been short term and thus have not provided information on the long-term outcomes of ADHD treatment. Since the medical treatment of many children with ADHD, especially those with more severe symptoms or co-morbid disorders, has to be continued for several years, recent studies have shifted their focus from the acute effectiveness of stimulants or non-stimulant drugs to the long-term outcomes of medications for ADHD. Evidence has shown that stimulants, along with the non-stimulants atomoxetine and extended-release guanfacine, are continuously effective for 24-month treatment periods with few and tolerable adverse effects.
Literatur
1.
Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 2007; 119 Suppl. 1: S99–106PubMed
2.
Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115(6): e749–57PubMed
3.
Wolraich ML, Hannah JN, Pinnock TY, et al. Comparison of diagnostic criteria for attention deficit hyperactivity disorder in a county-wide sample. J Am Acad Adol Psychiatry 1996; 35(3): 319–24
4.
Cox ER, Halloran DR, Homan SM, et al. Trends in the prevalence of chronic medication use in children: 2002–2005. Pediatrics 2008; 122(5): e1053–61PubMed
5.
Olfson M, Gameroff MJ, Marcus SC, et al. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003; 160(6): 1071–7PubMed
6.
van den Ban E, Souverein P, Swaab H, et al. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate-or extended-release methyl-phenidate or atomoxetine in the Netherlands during 2001–2006. J Child Adolesc Psychopharmacol 2010; 20(1): 55–61PubMed
7.
Vinker S, Vinker R, Elhayany A. Prevalence of methyl-phenidate use among Israeli children: 1998–2004. Clin Drug Investig 2006; 26(3): 161–7PubMed
8.
Sankaranarayanan J, Puumala SE, Kratochyil CJ. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003. Curr Med Res Opin 2006; 22(8): 1475–91PubMed
9.
Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283(8): 1059–60
10.
Wigal SB. Efficiency and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23 Suppl. 1: 21–31
11.
Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of ADHD with methylphenidate. CNS Drugs 2004; 18(4): 243–50PubMed
12.
Teicher MH, Polcari A, Foley M, et al. Methylphenidate blood levels and therapeutic response in children with ADHD: effects of different dosing regimens. J Child Adolesc Psychopharmacol 2006; 16(4): 416–31PubMed
13.
NIH Consensus Development Program-110. Diagnosis and treatment of attention deficit hyperactivity disorder: consensus development conference statement. Bethesda (MD): National Institutes of Health, 1998
14.
Weiss M, Jain U, Garland J. Clinical suggestions for management of stimulant treatment in adolescents. Can J Psychiatry 2000; 45(8): 717–23PubMed
15.
Biederman J, Petty CR, Monuteaux MC, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry 2010; 167(4): 409–17PubMed
16.
Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 2009; 29(6): 656–79PubMed
17.
Chavez B, Sopko Jr MA, Ehret MJ, et al. An update on central venous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother 2009; 43(6): 1084–95PubMed
18.
Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethyl-phenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 2008; 22(8): 693–704PubMed
19.
Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficiency in attention deficit/hyperactivity disorder. Neuro-psychopharmacology 2002; 27(5): 699–711
20.
Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83–91PubMed
21.
Dopheide JA. ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients. Am J Health Syst Pharm 2005; 62(14): 1502–9PubMed
22.
Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(7): 894–921PubMed
23.
Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment and clinical implications. Pediatrics 2005; 115(6): 1734–46PubMed
24.
Pliszka S, Crismon ML, Hughes CW, et al. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45(6): 642–57PubMed
25.
Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006; 8(4): 4
26.
Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114(1): e1–8PubMed
27.
May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010; 70(1): 15–40PubMed
28.
Reimherr FW, Hedges DW, Strong RE, et al. Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial. Neuropsychiatr Dis Treat 2005; 1(3): 245–51PubMed
29.
Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115(6): e749–57PubMed
30.
Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23 Suppl. 1: 43–9
31.
Findling RL, Wigal SB, Bukstein OG, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multi-center, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther 2009; 31(8): 1844–55PubMed
32.
Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45(11): 1284–93PubMed
33.
Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005; 147(3): 348–54PubMed
34.
Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005; 44(10): 1015–23PubMed
35.
McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44(6): 530–8PubMed
36.
Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004; 43(7): 802–11PubMed
37.
Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004; 43(5): 559–67PubMed
38.
Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 176–85PubMed
39.
Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007; 61(5): 694–9PubMed
40.
Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol 2006; 16(6): 713–24PubMed
41.
Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006; 149(1): 112–9PubMed
42.
Newcorn JH, Michelson D, Kratochvil CJ, et al. Low-dose atomoxetine for maintenance treatment of attention-deficit/ hyperactivity disorder. Pediatrics 2006; 118(6): e1701–6PubMed
43.
Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45(8): 919–27PubMed
44.
Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19(3): 215–26PubMed
45.
Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008; 13(12): 1047–55PubMed
46.
The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder: Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56(12): 1073–86
47.
Hechtman L, Abikoff H. Multimodal treatment plus stimulants vs stimulant treatment in ADHD children: results from a two-year comparative treatment study. Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 1995 Oct 18–26; New Orleans (LA)
48.
MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113(4): 754–61
49.
Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007; 46(8): 989–1002PubMed
50.
Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007; 41(3): 222–30PubMed
51.
Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41(7): 776–84PubMed
52.
Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005; 22(5): 498–512PubMed
53.
Starr HL, Kemner J.Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc 2005; 97(10 Suppl. ): 11S–6SPubMed
54.
Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165(6): 721–30PubMed
55.
Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005; 9(1): 275–89PubMed
56.
Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366(9481): 237–48PubMed
57.
Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121(1): e73–84PubMed
58.
Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 155–65PubMed
59.
Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010; 24(9): 755–68PubMed
60.
Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/ hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006; 27(1): 1–10PubMed
61.
Faraone SV, Biederman J, Monuteaux M, et al. Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on growth. J Child Adolesc Psychopharmacol 2005; 15(2): 191–202PubMed
62.
Gross MD. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Pediatrics 1976; 58(3): 423–31PubMed
63.
Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 1998; 102 (2 Pt 3): 501-6
64.
Kramer JR, Loney J, Ponto LB, et al. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 2000; 39(4): 517–24PubMed
65.
Faraone SV, Biederman J, Morley CP, et al. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47(9): 994–1009PubMed
66.
Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46(8): 1015–27PubMed
67.
Charach A, Figueroa M, Chen S, et al. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006; 45(4): 415–21PubMed
68.
Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 2007; 46(9): 1138–47PubMed
69.
Spencer TJ, Faraone SV, Biederman J, et al. Dose prolonged therapy with a long-acting stimulant suppresses growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 2006; 45(5): 527–37PubMed
70.
Zachor DA, Roberts AW, Hodgens JB, et al. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil 2006; 27(2): 162–74PubMed
71.
Biederman J, Spencer TJ, Monuteaux MC, et al. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 2010; 157(4): 635–40PubMed
72.
Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116(1): e74–80PubMed
73.
Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007; 17(5): 689–700PubMed
74.
Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: what is a physician to do? Pediatrics 2006; 118(3): 1215–9PubMed
75.
Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007; 120(6): e1494–501PubMed
76.
Samuels JA, Franco K, Wan F, et al. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21(1): 92–5PubMed
77.
Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40(5): 525–9PubMed
78.
Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007; 61(5): 706–12PubMed
79.
Weisler RH, Biederman J, Spencer TJ, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005; 10(12 Suppl. 20): 35–43PubMed
80.
Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009; 155(1): 84–9PubMed
81.
Wilens TE, Biederman J, Lerner M, et al. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/ hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004; 24(1): 36–41PubMed
82.
83.
Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354(14): 1445–8PubMed
84.
Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010; 33(10): 821–42PubMed
85.
Spencer T, Biederman J, Coffey B, et al. Tourette disorder and ADHD. Adv Neurol 2001; 85: 57–77PubMed
86.
Varley CK, Vincent J, Varley P, et al. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 2001; 42(3): 228–33PubMed
87.
Roessner V, Robatzek M, Knapp G, et al. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 2006; 48(7): 616–21PubMed
88.
Palumbo D, Spencer T, Lynch J, et al. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 2004; 14(2): 185–94PubMed
89.
Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003; 42(4): 424–33PubMed
90.
Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999; 56(4): 330–6PubMed
91.
Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999; 103 (4 Pt 1): 730–7PubMed
92.
Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48(9): 884–93PubMed
93.
Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003; 111(1): 97–109PubMed
94.
Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder: therapeutic implications. CNS Drugs 2005; 19(8): 643–55PubMed
95.
Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165(5): 597–603PubMed
96.
Burke JD, Loeber R, Lahey BB. Which aspects of ADHD are associated with tobacco use in early adolescence? J Child Psychol Psychiatry 2001; 42(4): 493–502PubMed
97.
Faraone SV, Biederman J, Wilens TE, et al. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 2007; 37(12): 1743–52PubMed
98.
Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111(1): 179–85PubMed
99.
Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J Atten Disord 2002; 6 Suppl. 1: S65–71PubMed
100.
Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk of substance use disorder. Pediatrics 1999; 104(2): e20PubMed
101.
Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008; 162(10): 916–21PubMed
102.
Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998; 31(6): 533–44PubMed
103.
Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165(5): 604–9PubMed
104.
Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol 2005; 15(5): 751–63PubMed
105.
Elkins IJ, McGue M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 2007; 64(10): 1145–52PubMed
106.
Fuemmeler BF, Kollins SH, McClernon FJ. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol 2007; 32(10): 1203–13PubMed
107.
Modesto-Lowe V, Danforth JS, Neering C, et al. Can we prevent smoking in children with ADHD: a review of the literature. Conn Med 2010; 74(4): 229–36PubMed
108.
Perwien AR, Faries DE, Kratochvil CJ, et al. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 2004; 25(4): 264–71PubMed
109.
Escobar R, Schacht A, Wehmeier PM, et al. Quality of life and attention-deficit/hyperactivity disorder core symptoms. J Clin Psychopharmacol 2010; 30(2): 145–51PubMed
110.
Matza LS, Rentz AM, Secnik K, et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25(3): 166–74PubMed
111.
Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity isorder: results from a Taiwanese sample. Aust N Z J Psychiatry 2007; 41(12): 998–1004PubMed
112.
Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q 2008; 79(2): 133–7PubMed
113.
Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/ hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007; 28(4): 265–73PubMed
114.
Galéra C, Melchior M, Chastang JF, et al. Childhood and adolescent hyperactivity-inattention symptoms and academic achievement 8 years later: the GAZEL Youth study. Psychol Med 2009; 39(11): 1895–906PubMed
115.
Scheffler RM, Brown TT, Fulton BD, et al. Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 2009; 123(5): 1273–9PubMed
116.
Powers RL, Marks DJ, Miller CJ, et al. Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. J Child Adolesc Psychopharmacol 2008; 18(5): 449–59PubMed
117.
Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009; 124(1): 71–8PubMed
118.
Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006; 36(2): 167–79PubMed
119.
Bojerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry 2010; 71(12): 1590–7
120.
Marchant BK, Reimherr FW, Halls C, et al. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann Clin Psychiatry 2010; 22(3): 196–204PubMed
121.
Rösler M, Retz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 2010; 11(5): 709–18PubMed
122.
Wender PH, Reimherr FW, Marchant BK, et al. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 2011; 15(1): 36–45PubMed
123.
Rösler M, Fischer R, Ammer R, et al. A randomized, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259(2): 120–9PubMed
124.
Adler LA, Spencer T, McGough JJ, et al. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009; 12(5): 449–59PubMed
125.
Alder LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008; 12(3): 248–53
126.
Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005; 66(3): 294–9PubMed
127.
Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009; 29(1): 44–50PubMed
128.
Spencer TJ. Issues in the management of patients with complex attention-deficit hyperactivity disorder syndromes. CNS Drugs 2009; 23 Suppl. 1: 9–20PubMed
Metadaten
Titel
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder
Current Status of Knowledge
verfasst von
Yu-Shu Huang
Dr Ming-Horng Tsai
Publikationsdatum
01.07.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11589380-000000000-00000

Weitere Artikel der Ausgabe 7/2011

CNS Drugs 7/2011 Zur Ausgabe

Short Communication

Rituximab for Secondary Progressive Multiple Sclerosis

Adis Drug Profile

Vilazodone

Review Article

Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder

Leading Article

Enhancing CNS Repair in Neurological Disease

Therapy in Practice

Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder

Therapy in Practice

Transdermal Rivastigmine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise